Abstract
1. Equivalent oral dosages (800 mg, 21.6 mmol) of standard (Lithicarb) and sustained-release (Priadel) lithium carbonate preparations were administered using a randomised cross-over design to six patients receiving long-term lithium maintenance and eight healthy student volunteers. 2. In both patients and students there were no significant differences between the two lithium preparations for plasma lithium level curves, bioavailability or total urinary excretion rates. 3. There were no differences in peak lithium concentrations (C max) between the two preparations in both patients and students, although the times to maximal levels (T max) were delayed after Priadel in patients and volunteers. 4. These data indicate that Priadel is a delayed-release rather than a true sustained-release preparation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Progress in Neuro-Psychopharmacology and Biological Psychiatry
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
